Sai Life Sciences IPO Allotment: How To Check Status Online? Latest GMP Hints At 13% Premium Listing

Sai Life Sciences IPO: The basis of allotment of Rs 3,042.62 crore worth Sai Life Sciences IPO has been finalised on December 16, 2024. The company is scheduled to list on BSE and NSE later this week, and its latest grey market premium (GMP) signalled for a nearly 13% premium debut. Sai Life Sciences IPO received healthy demand from investors categories.

Sai Life Sciences IPO Allotment:

Investors can check the application of their status through BSE, NSE and registrar of the IPO, Kfin Technologies.

To Check Your Application Status Via Kfin Technologies, Click On The Link Below:

https://ipostatus.kfintech.com/

Step 1: After clicking the link, there will be an option called 'Select IPO'. Click on it and select 'Sai Life Sciences Limited'.

Step 2: The second process is to choose between your Application Number, Demat account number, or PAN card number to review your application status.

Step 3: Then add into the captcha code and click on SUBMIT.

To Check Your Application Status Via BSE, Click On The Link Below:

https://www.bseindia.com/investors/appli_check.aspx

Step 1: First, select the issue type which in Sai Life Sciences' case is 'Equity'.

Step 2: Then Select the issue name, which will be 'Vishal Mega Mart Limited'.

Step 3: Add your Application Number or PAN Card Number to process ahead. Lastly, Click on Search.

Sai Life Sciences IPO GMP Today:

As per Investor Grain, Sai Life Sciences IPO's last GMP is ₹70, last updated Dec 16th 2024 05:54 PM. With a price band of 549.00, Sai Life Sciences IPO's estimated listing price is ₹619 (cap price + today's GMP). The expected percentage gain/loss per share is 12.75%.

Sai Life Sciences IPO Listing:

After the basis of allotment, the initiation of refunds or credit to eligible shareholders' demat accounts is likely to take place on December 17. The IPO is expected to list on December 18 tentatively. The listing will take place on BSE and NSE.

According to SBI Securities, the company is valued at FY24 P/E and EV/EBITDA multiples of 137.9x and 38.6x respectively based on the upper price band on the postissue capital. Sai Life Sciences is one of the largest integrated CRDMOs in India among listed peers and has established capabilities across the discovery, drug development and commercial manufacturing value chain.

Further, the brokerage pointed out that although the company may seem slightly overvalued compared to its closest peer, the company has delivered Revenue/EBITDA/PAT CAGR of 29.8%/ 53.4%/264.7% respectively between FY22-FY24. Further, repayment of debt from the proceeds of the issue will reduce finance costs by ~Rs 56 cr thus augmenting profitability going forward.

The IPO was a combination of a fresh issue worth Rs 950 crore and an offer for sale (OFS) of up to 3,81,16,934 equity shares. The 100% book building had a price band of Rs 522 to Rs 549 per share. The IPO opened on December 11 and closed on December 13.

On its final day of IPO, the IPO was oversubscribed by 10.27 times.

Sai Life Sciences Ltd (SLSL) is an innovator-focused contract research, development & manufacturing organization (CRDMO) providing end-to-end services across the drug discovery, development, and manufacturing value chain for small molecule New Chemical Entities (NCE) to global pharmaceutical innovator companies and biotechnology firms.